From the Challenger explosion and $0.25-a-minute phone calls to the Tylenol murders and 1-900 numbers, here are 23 real ...

A short term relationship may be costly to a fickle first owner, but can provide an affordable alternative to buying a new ...

Discover a practical blueprint for building a modern, intelligence-driven threat program aligned with enterprise risk and ...

A longtime HIV advocate turned anal cancer survivor, Daniel G. Garza utilizes humor and candor to call out stigma, encourage open conversation, and inspire healing in communities that are often placed ...

Q3 2025 Earnings Call Transcript November 10, 2025 Compugen Ltd. beats earnings expectations. Reported EPS is $-0.07461, ...

Listen and subscribe to Morningstar’s The Long View from your mobile device: Apple Podcasts | Spotify Today’s guest on The ...

Smart & Safe Florida, which led the 2024 legalization campaign, accuses the state of delaying Supreme Court review of its new ...

The Nasdaq 100 enjoyed one of those well-timed Friday afternoon rallies (1.9% off morning trading lows) to somewhat ease ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...